Overview

Sildenafil IV Bolus Study

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, tolerability and pharmacokinetics of intravenous sildenafil (10 mg) administered as a bolus injection to patients with Pulmonary Arterial Hypertension already receiving and stable on oral Revatio 20 mg TID.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Sildenafil Citrate